anthrax lethal factor

anthrax lethal factor

(an'thraks lē'thăl fak'tŏr),
A protein secreted by Bacillus anthracis, that selectively induces apoptosis of activated macrophages by cleaving the amino-terminal extension of mitogen-activated protein kinase kinases (MKKs). This action may allow the bacteria to avoid detection by the host's innate immune system.
References in periodicals archive ?
The safety, stability and bioavailability of these candidates will be improved with the goal of use in humans as an antidote to anthrax lethal factor intoxication.
Bound to these molecules is a protein fragment, or peptide, that gets cleaved in two in the presence of anthrax lethal factor, a toxin produced by the bacterium.
After screening 10,000 chemicals in 3 days, the researchers found one compound, called DS-998, that blocked the activity of anthrax lethal factor.
The Genes To Leads(R) technology has been successfully applied to 15 targets on a contract basis for a growing number of pharmaceutical and biotech companies, and as the basis for Cengent's own highly successful in-house programs for orally active PTP-1B inhibitors (for treatment of type II diabetes and obesity) and anthrax lethal factor inhibitors.
has developed a solution-based assay for anthrax lethal factor, a toxin produced by the B.
The Genes To Leads technology has been successfully applied to 15 targets on a contract basis for a growing number of pharmaceutical and biotech companies, and is the basis for Cengent's own highly successful in-house programs for orally active PTP-1B inhibitors (for treatment of type II diabetes and obesity), and anthrax lethal factor inhibitors.
In October 2002, Cengent announced the issuance of the first United States Patent describing small-molecule inhibitors of anthrax lethal factor.
A small-molecule that can inhibit anthrax lethal factor and is cell-permeable can potentially provide significant protection against anthrax as prophylactic and acute therapy.
Patent and Trademark Office for a family of drug-like molecules that inhibit the activity of anthrax lethal factor.
A small molecule that can inhibit the action of anthrax lethal factor can potentially provide significant protection against anthrax for prophylaxis and acute therapy, SBI reports.
SBI) announced today its award from the National Institutes of Health (NIH) of a Small Business Innovation Research (SBIR) Phase II grant for SBI's continued development of an anthrax lethal factor inhibitor.
Patent Office for a family of drug-like molecules that inhibit the activity of anthrax lethal factor.